trial

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

NCTId NCT00986531
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 59 (actual)
Sponsored by AstraZeneca
Primary completion 2011-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
59 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2009-11
Primary completion
2011-10
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
AZD8529

Sponsors

AstraZenecaLead Sponsor

Investigators

1
Raquel Gur, MDPrincipal Investigator

Sites

1 total
Philadelphia, United States

Facts & assertions

4 sourced
Enrollment
59
Phase
PHASE1
Primary Completion Date
2011-10
Status
COMPLETED
relationships
The graph out of here
drug
AZD8529
drug
lead_sponsor
AstraZeneca
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Raquel Gur, MD
person